The associations of serum valine with mild cognitive impairment and Alzheimer's disease.

Abstract

BACKGROUND:

The introduction of metabolomics makes it possible to study the characteristic changes of peripheral metabolism in Alzheimer's disease (AD). Recent studies have found that the levels of valine are related to mild cognitive impairment (MCI) and AD.

AIMS:

This study aimed to further clarify the characteristics of valine levels in MCI and AD.

METHODS:

A total of 786 participants from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI-1) cohort were selected to evaluate the relationships between serum valine and cerebrospinal fluid (CSF) biomarkers, brain structure (magnetic resonance imaging, MRI), cerebral glucose metabolism (18F-fluorodeoxyglucose-positron emission tomography, FDG-PET), and cognitive declines, through different cognitive subgroups.

RESULTS:

Serum valine was decreased in patients with AD compared with cognitive normal (CN) and stable MCI (sMCI), and in progressive MCI (pMCI) compared with CN. Serum valine was negatively correlated with CSF total tau (t-tau) and phosphorylated tau (p-tau) in pMCI. Serum valine significantly predicted conversion from MCI to AD. In addition, serum valine was related to the rate of change of cerebral glucose metabolism during the follow-up period in pMCI.

CONCLUSIONS:

Serum valine may be a peripheral biomarker of pMCI and AD, and its level predicts the progression of MCI to AD. Our study may help to reveal the metabolic changes during AD disease trajectory and its relationship to clinical phenotype.

• Authors: Yong-Lan Xiong, Joseph Therriault, Shu-Jiang Ren, Xiao-Jun Jing, Hua Zhang, Alzheimer’s Disease Neuroimaging Initiative
• Journal: Aging clinical and experimental research (Aging Clin Exp Res) Vol. 34 Issue 8 Pg. 1807-1817 (Aug 2022) ISSN: 1720-8319 [Electronic] Germany
• PMID: 35362856 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Amyloid beta-Peptides
• Biomarkers
• tau Proteins
• Valine
• Glucose

Topics

• Alzheimer Disease (cerebrospinal fluid)
• Amyloid beta-Peptides (metabolism)
• Biomarkers (metabolism)
• Brain (diagnostic imaging, metabolism)
• Cognitive Dysfunction (cerebrospinal fluid, diagnostic imaging)
• Disease Progression
• Glucose
• Humans
• Positron-Emission Tomography
• Valine
• tau Proteins